APL180
Phase 2Small molecule
NovartisAPL180 is one of 67 small molecule programs targeting Familial Hypercholesterolemia. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
166 competitors in Heart Disease
#DrugCompanyPhaseTrials
1Aldactone
PfizerPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Biaxin
AbbViePhase 3
Lopid
PfizerPhase 3
Ozempic
Novo NordiskPhase 3
Depo-Provera
Eli LillyPhase 3
Activella
Eli LillyPhase 3
Vivarin
HHikma Pharmaceuticals LLC
Phase 3
Levophed
GGeneral Hospital of Ningxia Medical University
Phase 3
Comparator: Statins
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Familial Hypercholesterolemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for APL180. EMBL-EBI & Wellcome Sanger Institute.
- [4]